Rogco LP Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Rogco LP acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 990 shares of the medical research company’s stock, valued at approximately $401,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. NBC Securities Inc. lifted its holdings in shares of Thermo Fisher Scientific by 125,200.0% during the first quarter. NBC Securities Inc. now owns 2,506 shares of the medical research company’s stock valued at $1,246,000 after purchasing an additional 2,504 shares during the last quarter. Harbor Investment Advisory LLC boosted its position in shares of Thermo Fisher Scientific by 30.5% in the 1st quarter. Harbor Investment Advisory LLC now owns 389 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 91 shares during the period. Finally, Merit Financial Group LLC increased its stake in Thermo Fisher Scientific by 19.2% in the 1st quarter. Merit Financial Group LLC now owns 11,746 shares of the medical research company’s stock worth $5,845,000 after purchasing an additional 1,895 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $583.53.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $484.70 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $620.00. The business’s 50-day moving average price is $478.98 and its two-hundred day moving average price is $446.98. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $183.03 billion, a P/E ratio of 28.03, a price-to-earnings-growth ratio of 2.51 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.